<?xml version="1.0" encoding="UTF-8"?>
<p id="par0105">Umifenovir is an antiviral agent that has been used for influenza treatment and has shown activity against SARS-CoV in vitro [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0195" ref-type="bibr">39</xref>]. Its activity against SARS-CoV-2 was investigated recently at a dose of 200 mg every 8 h in combination with Lopinavir/Ritonavir in a retrospective cohort Chinese study [
 <xref rid="bib0195" ref-type="bibr">39</xref>]. Results showed better clinical response in the combination group in comparison with the Lopinavir/Ritonavir monotherapy group. Umifenovir is currently being tested in seven randomized trials for the treatment of COVID-19 [
 <xref rid="bib0190" ref-type="bibr">38</xref>].
</p>
